Health & Research Goals
PT-141 (Bremelanotide / Vyleesi)
PT-141 (Bremelanotida / Vyleesi)
PT-141 (bremelanotide) is a synthetic cyclic heptapeptide melanocortin receptor agonist derived from alpha-melanocyte-stimulating …
Primary Description
PT-141 (bremelanotide) is a synthetic cyclic heptapeptide melanocortin receptor agonist derived from alpha-melanocyte-stimulating hormone (alpha-MSH), itself a structural descendant of Melanotan II. Unlike PDE5 inhibitors (sildenafil, tadalafil) which act peripherally via vascular smooth muscle, PT-141 acts centrally on melanocortin-3 and melanocortin-4 receptors in the hypothalamus and limbic system to directly enhance sexual desire and arousal neurologically. PT-141 holds the distinction of being FDA-approved (as Vyleesi, 2019) for hypoactive sexual desire disorder (HSDD) in premenopausal women — making it one of the very few peptides in this biohacker catalog with a regulatory approval. The community also uses it extensively off-label for sexual dysfunction in men, including cases non-responsive to PDE5 inhibitors.
Key Benefits
- Sexual arousal
- Libido enhancement
- Works centrally
Lyophilized: store at -20C. Reconstituted: refrigerate at 2-8C, use within 30 days. Vyleesi (FDA-approved auto-injector): room temperature storage per package insert. Half-life ~2.7 hours; inject 30-60 minutes before activity.
Demonstrated Effects
- Centrally-mediated enhancement of sexual desire and arousal in women (FDA-approved for HSDD in premenopausal women)
- Improved erectile function in men including those non-responsive to PDE5 inhibitors
- Rapid onset: effects begin within 30-60 minutes, duration 6-12 hours
- Central (CNS) mechanism — acts on desire/arousal itself, not just vascular erectile mechanics
- Effective across psychogenic, neurogenic, and mixed-etiology sexual dysfunction
- Does not meaningfully interact with alcohol (unlike flibanserin — competitive female HSDD drug)
- High subcutaneous bioavailability (~100%)
- FDA-approved safety profile well characterized in Phase 3 clinical trials
Proposed Mechanisms of Action
1. MC4R Agonism — Central Sexual Arousal Pathway
Activation of melanocortin-4 receptors in the hypothalamus (paraventricular nucleus) and limbic regions initiates pro-sexual neurological signaling including dopaminergic and oxytocinergic pathways. This is the primary mechanism driving sexual desire and arousal enhancement.
Core mechanism — fundamentally different from peripheral vasodilatory drugs. Acts on the 'desire' component of sexual function.
2. MC3R Agonism — Secondary Metabolic Effects
MC3R activation contributes to energy homeostasis and anti-inflammatory signaling. Less relevant to sexual effects but contributes to the broader pharmacological profile.
Minor contributor to appetite suppression and potential anti-inflammatory effects observed by some community members.
3. MC1R Agonism — Pigmentation Side Effect
PT-141 retains partial MC1R agonism (less than Melanotan II but present at higher dose or cumulative exposure). Chronic use beyond 8 doses/month can cause hyperpigmentation particularly on face, gums, and breasts.
Responsible for the hyperpigmentation side effect risk with overuse. Limits recommended maximum dosing frequency.
Research Evidence & Clinical Data
Investigated Applications
Female Hypoactive Sexual Desire Disorder (HSDD)
Anecdotal: HighThe FDA-approved indication. Women with HSDD report significant improvement in sexual desire, arousal, and reduction in distress. The on-demand nature (inject before activity) is preferred by many over daily dosing flibanserin.
Preclinical basis: Phase 3 RCTs: bremelanotide significantly improved sexual desire scores and reduced distress vs. placebo in premenopausal women with HSDD. FDA approved June 2019.
Male Sexual Dysfunction / Erectile Dysfunction
Anecdotal: HighExtensive community off-label use in men for erectile dysfunction (including PDE5-non-responsive), low libido, and desire enhancement. The CNS mechanism means it works for psychogenic ED where PDE5 inhibitors provide only partial benefit.
Preclinical basis: Early Phase I/II trials (Wessells et al., Phase II ED data) demonstrated dose-dependent improvements in erectile function scores including in PDE5 non-responders. Off-label prescribing in men is legal and common in sexual medicine practices.
Libido Enhancement — Healthy Individuals
Anecdotal: HighCommunity members without diagnosed HSDD or ED use PT-141 for recreational libido enhancement — heightened desire, stronger arousal, enhanced sexual experience. Reports of more intense orgasms in both men and women.
Preclinical basis: MC4R agonism in the hypothalamic/limbic circuit for pro-sexual behavior well established in animal models. Phase I accidental overdose (researcher injecting double dose) produced 8-hour erection — first documented human data on potency.
Scientific References
- 1.FDA Prescribing Information — Vyleesi (bremelanotide injection) 1.75 mgFDA / Palatin Technologies2019
Official FDA prescribing information for Vyleesi. Defines approved indication (premenopausal women, HSDD), standard dose 1.75 mg SubQ, maximum 8 doses/month, contraindications, and side effect profile.
- 2.PT-141: a melanocortin agonist for the treatment of sexual dysfunctionAnn N Y Acad Sci2003
- 3.
- 4.
Safety Profile
Common Side Effects
- Nausea — most common (~40% in clinical trials); usually peaks at 1-2 hours post-injection, resolves by 4-6 hours
- Flushing and facial warmth (~20% in trials)
- Headache (~11%)
- Injection site reactions (~13%) — bruising, redness, tingling
- Transient blood pressure increase (systolic +6 mmHg average — usually well tolerated in healthy individuals)
- Hyperpigmentation of face, gums, or breasts with use exceeding 8 doses/month — may be irreversible
- Yawning and stretching (common CNS signal of onset — generally harmless)
- Spontaneous erections (men — can be unwanted in non-sexual context)
- Priapism (rare — risk increased significantly if combined with PDE5 inhibitors)
- Slower gastric motility reducing oral absorption of other medications taken concurrently
- Nausea
- Flushing
- Headache
Contraindications
- Uncontrolled hypertension or cardiovascular disease — transient BP elevation (systolic +6 mmHg, diastolic +3 mmHg) occurs routinely; in high-risk patients this is contraindicated
- History of priapism or conditions predisposing to prolonged erection (sickle cell, penile anatomy issues)
- Concurrent PDE5 inhibitor use (tadalafil, sildenafil, vardenafil) — risk of priapism and hypertensive episode
- Pregnancy — melanocortin activation has reproductive hormonal effects; avoid
- Breastfeeding — no data
- Hypersensitivity to PT-141 or any component
- Postmenopausal women (not FDA-approved; limited efficacy data)
- Active psychiatric conditions where sexual disinhibition would be clinically problematic
- Uncontrolled hypertension
- Cardiovascular disease
Pre-Use Screening Checklist
Baseline blood pressure should be measured. PT-141 is contraindicated in uncontrolled hypertension. Even controlled hypertension warrants caution and monitoring.
Concurrent use of PT-141 and PDE5 inhibitors (sildenafil, tadalafil, vardenafil) carries significant risk of priapism in men and additive hypertensive effects. International Peptide Society explicitly recommends against concurrent use.
PT-141 can cause erections and in susceptible individuals or at high doses, prolonged erections. Prior priapism history is a contraindication.
Document any moles or pigmented lesions before use. Chronic overuse (>8/month) can cause facial or mucosal hyperpigmentation that may be permanent.
Legal & Regulatory Status
FDA APPROVED (2019) under brand name Vyleesi — indicated for treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. Approved dose: 1.75 mg SubQ, on-demand, maximum 8 doses/month. Use in men and postmenopausal women is off-label.
Not listed on WADA Prohibited List. Not classified as a prohibited performance-enhancing substance in competitive sport.
Not approved by COFEPRIS for any indication. Available as research peptide. Vyleesi brand product not commercially available in Mexico.
Not approved by EMA. Gedeon Richter (Palatin's EU partner) evaluated Phase 3 data for possible EU application post-FDA approval; no EMA marketing authorization granted as of 2025. Not commercially available in EU.
Not approved by TGA as a therapeutic good. Research peptide status only. Vyleesi not registered or commercially available.
Research Protocols
Dosing Protocols
FDA-approved female HSDD dose (Vyleesi)
Subcutaneous auto-injector (abdomen or thigh)Male off-label / community libido and ED protocol
Subcutaneous injection (abdomen or thigh, insulin syringe)Low-dose tolerance testing / first use
SubcutaneousRoutes of Administration
Subcutaneous injection
Most commonStandard route for research peptide PT-141 and Vyleesi auto-injector. Inject into lower abdomen or thigh with insulin syringe (29-31 gauge) or use Vyleesi autoinjector device for the approved product.
Use 1 mL insulin syringe for reconstituted research peptide. 45-degree injection angle. Massage site gently post-injection. Rotate sites.
Intranasal (compounded nasal spray)
Less commonCompounding pharmacies sometimes formulate PT-141 as a nasal spray (1-10 mg/mL). Historically the original PT-141 development pathway used intranasal delivery. Bioavailability lower than SubQ; dose adjustments needed.
Less reliable absorption than SubQ. 1-2 sprays per nostril of 1-2 mg/mL formulation; titrate. Onset may be slower and more variable.
Reconstitution Guide
Bacteriostatic water (0.9% benzyl alcohol). Sterile water acceptable but shorter shelf life.
1. Allow vial to reach room temperature. 2. Wipe septum with alcohol. 3. Inject bacteriostatic water slowly down vial wall. 4. Gently swirl until dissolved — do NOT shake. 5. Solution should be clear and colorless. 6. Label with date.
For 10 mg vial with 5 mL bacteriostatic water = 2 mg/mL. A 1 mg dose = 0.5 mL (50 units on U100 insulin syringe). A 2 mg dose = 1 mL.
Refrigerate at 2-8C. Use within 30 days. Protect from light.
Store at -20C long-term. Stable at room temperature for several weeks. Desiccated, protect from light and moisture.
Inject 45-60 minutes before anticipated sexual activity. Effects onset 30-60 min, duration 6-12 hours. Evening use preferred for managing nausea. Have a light meal 20-30 minutes before injection. Do not exceed 1 dose per 24 hours.
Pharmacokinetics
| Half-Life | 2.7 hours (range 1.9-4.0 hours). Rapid elimination supports on-demand dosing with effects lasting 6-12 hours due to receptor-mediated downstream signaling persisting beyond plasma half-life. |
| Absorption | Subcutaneous bioavailability approximately 100%. Peak plasma concentration reached within 1 hour (range 0.5-1.0 hours) after SubQ injection. |
| Distribution | Plasma protein binding 21%. Crosses blood-brain barrier to reach hypothalamic and limbic MC3R/MC4R. Volume of distribution approximately 40-50 L. |
| Metabolism | Metabolized via hydrolysis of peptide bonds. No significant cytochrome P450 enzyme involvement. Excreted 64.8% in urine, 22.8% in feces. Slows gastric motility — reduces oral bioavailability of naltrexone and indomethacin taken concurrently. |
| Molecular Structure | Cyclic heptapeptide lactam: Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH. MW 1025.2 Da. CAS 189691-06-3. Cyclized structure provides greater metabolic stability than linear alpha-MSH. |
Monitoring & Risk Management
Ongoing Monitoring Steps
- Blood pressureMeasure BP 1-2 hours post-injection for first few uses. Persistent elevation above 140/90 warrants dose reduction or discontinuation.Check: First 2-3 uses, then as needed
- Skin pigmentationWatch for hyperpigmentation of face, gums, or breasts. Any new or darkening skin changes warrant frequency reduction and dermatology consultation.Check: Monthly
- Erection duration (men)Any erection exceeding 4 hours = medical emergency (priapism). Particularly important for first-time users and those who previously used PDE5 inhibitors.Check: Each use
Critical Warning Signs
- Erection lasting 4 or more hours (priapism)Emergency medical care required — priapism can cause permanent erectile damage if untreated. Do not wait to see if it resolves on its own beyond 4 hours.Urgency: IMMEDIATE
- Severe headache, vision changes, or blood pressure exceeding 180/110 after injectionDiscontinue PT-141 and seek emergency care. May represent hypertensive crisis especially if combined with other vasopressor agents.Urgency: IMMEDIATE
- Unexplained hyperpigmentation on face, gums, or breastsDiscontinue PT-141. Consult dermatologist. Reduce dosing frequency to maximum 4x/month if restarting. Hyperpigmentation may not fully reverse.Urgency: Within 1 week if persistent
- Severe persistent nausea and vomiting (>6 hours)Reduce dose to 1 mg or 0.5 mg. Antiemetic pretreatment (ondansetron) may help for future use. If dehydration develops, seek medical care.Urgency: Within 24-48 hours
Featured in Stacking Protocols
Community-researched combinations involving this compound
Tadalafil (low-dose daily)
Central + Peripheral Sexual Function StackCombine PT-141 central desire/arousal enhancement with tadalafil peripheral vascular erectile support for comprehensive male sexual function optimization
PT-141 activates the desire and arousal neurological circuitry (MC4R, hypothalamus). Tadalafil maximizes vascular erectile mechanics (PDE5 inhibition, cGMP elevation, penile smooth muscle relaxation). These are completely complementary pathways. Clinical observation shows men who partially respond to PDE5 inhibitors often achieve full response when PT-141 is added.
IMPORTANT SAFETY NOTE: Do NOT use concurrently (same-day). Protocol option A: tadalafil 5 mg daily low-dose for baseline vascular support; PT-141 1-1.5 mg SubQ on activity days (not same-day as elevated tadalafil dose). Protocol option B: use one or the other — not both on the same day.
Oxytocin (intranasal)
Connection and Intimacy StackCombine PT-141 arousal enhancement with oxytocin bonding/intimacy facilitation
PT-141 drives sexual desire and arousal via melanocortin pathway. Intranasal oxytocin promotes emotional bonding, trust, and intimate connection. Community reports enhanced quality of sexual experience beyond mechanics.
PT-141 1-1.5 mg SubQ 45-60 min before + Intranasal oxytocin 24-40 IU (3-4 sprays) 15-20 min before activity. Very limited safety data for combination — individual tolerance assessment required.
Melanotan II (as precursor context only)
Melanotan II (as precursor context only) Synergy StackHistorical note: PT-141 was derived from MT-2 as a more selective compound with less tanning/melanogenesis activity
NOT recommended to combine. Both activate MC3R/MC4R and the combination provides no additional benefit while markedly increasing side effect burden (nausea, flushing, blood pressure). PT-141 is the more selective, lower-side-effect option when sexual function is the goal.
Choose one or the other — not both.